Vanessa Rojas
Family Medicine · Miami, FLNPI 1922498716
Payments from drug & device makers
Across 337 payments — averaging $148.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$45K
- Viiv Healthcare Company$3K
- Theratechnologies Inc.$597
- Merck$336
- Johnson & Johnson$190
- EMD Serono, Inc.$113
- plus $527 from 11 others
What the payments were for
- Consulting fees$4,6409%
- Speaking & faculty fees$32,67065%
- Travel & lodging$3,9848%
- Food & beverage$8,83818%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 128 | $45,347 |
| Viiv Healthcare Company | 129 | $3,022 |
| Theratechnologies Inc. | 24 | $597 |
| Merck | 15 | $336 |
| Johnson & Johnson | 9 | $190 |
| EMD Serono, Inc. | 4 | $113 |
| Lilly USA, LLC | 7 | $105 |
| Exact Sciences | 4 | $77 |
| Pfizer | 3 | $69 |
| Idorsia Pharmaceuticals US Inc | 4 | $67 |
| Novo Nordisk | 2 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $44 |
| Cranial Technologies, Inc | 2 | $43 |
| GSK | 1 | $25 |
| Napo Pharmaceuticals Inc | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Conmed Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$50,132 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 18 | $133,403 |
| Egrifta SvTesamorelin Acetate | 15 | $106,589 |
| RukobiaFostemsavir Tromethamine | 13 | $96,205 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 23 | $95,671 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 21 | $78,260 |
| DovatoDolutegravir Sodium/Lamivudine | 21 | $64,532 |
| JulucaDolutegravir/Rilpivirine | 15 | $50,325 |
| TivicayDolutegravir Sodium | 17 | $40,618 |
| Estradiol (Twice Weekly)Estradiol | 13 | $911 |
| Losartan Potassium | 25 | $464 |
| Ezetimibe | 11 | $383 |
| ValacyclovirValacyclovir Hcl | 12 | $351 |
| Levothyroxine Sodium | 12 | $335 |
| Atorvastatin Calcium | 23 | $275 |
| Rosuvastatin Calcium | 34 | $246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyRukobia, Dovato, Juluca, Tivicay | $3,022 | $251,67966 claims |
| Theratechnologies Inc.Egrifta Sv | $597 | $106,58915 claims |
| GileadBiktarvy | $45,347 | $95,67123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Miami
- Keila HooverMiami$33.7M
- Jorge CasoMiami$22.6M
- David WyattMiami$13.7M
- Jose CardenasMiami$13.2M
- Lazaro GarciaMiami$10.3M
- Ibrahim Menendez PerezMiami$8.9M
- Aniel Navarro MarinMiami$7.3M
- Gilberto SecoMiami$6.8M
- Ramon LeonMiami$6.3M
- Eddy CapoteMiami$6.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.